Related Experiment Video
Updated: Nov 12, 2025
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
19.2K
Unrecognized blood clotting factors
Hidehiko Saito1, Tetsuhito Kojima2
1National Hospital Organization Nagoya Medical Center, 4-1-1 Sanno-maru, Naka-ku, Nagoya, 460-0001, Japan. hi.saito@nnh.hosp.go.jp.
International Journal of Hematology
|March 20, 2021
Summary
This review examines unapproved clotting factors, clarifying their identities to prevent confusion in coagulation disorder research. It aims to distinguish these factors from already identified ones.
Area of Science:
- Hematology
- Biochemistry
- Medical Genetics
Background:
- Clotting factors were historically identified through rare hereditary coagulation disorders.
- Inconsistent naming conventions arose, leading to the same factors having multiple names.
- An international committee was established to standardize clotting factor nomenclature.
Purpose of the Study:
- To review clotting factors lacking official authorization.
- To determine if these unapproved factors are identical to known clotting factors.
Main Methods:
- Literature review of historical and current research on clotting factor nomenclature.
- Analysis of functional and biochemical data for unapproved clotting factors.
- Comparison of characteristics of unapproved factors with established clotting factors.
Main Results:
- Several clotting factors remain unassigned or lack official authorization.
- Preliminary analysis suggests some unapproved factors may be distinct entities.
- Further investigation is needed to definitively characterize these factors.
Conclusions:
- Standardizing clotting factor nomenclature is crucial for clear scientific communication.
- Clarifying the identity of unapproved factors will aid in understanding coagulation pathways.
- This review highlights the ongoing need for nomenclature refinement in hematology.
More Related Videos
Related Concept Videos
01:24Disorders of Hemostasis
1.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.6K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
10.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.6K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.2K
01:16Clot Retraction and Fibrinolysis
7.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
7.7K
01:09Coagulation
8.7K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.7K
01:06Coagulation
595
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
595